Johnson & Johnson (VIE:JNJ)
Austria · Delayed Price · Currency is EUR | Market Cap | 507.06B +40.5% |
| Revenue (ttm) | 80.06B +6.0% |
| Net Income | 22.78B +90.6% |
| EPS | 9.38 +90.5% |
| Shares Out | n/a |
| PE Ratio | 22.26 |
| Forward PE | 20.83 |
| Dividend | 4.49 (2.11%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 20 |
| Average Volume | 46 |
| Open | 210.05 |
| Previous Close | 211.40 |
| Day's Range | 210.05 - 212.60 |
| 52-Week Range | 128.32 - 214.30 |
| Beta | n/a |
| RSI | 62.26 |
| Earnings Date | Apr 14, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Johnson & Johnson presents new data showing high rates of complete skin clearance achieved at Week 24 and Week 52 in ICONIC-ADVANCE 1 and 2 studies Nearly 60% of adolescents treated with ICOTYDE achie...
Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength
Johnson & Johnson shows relative strength with a bull flag breakout attempt, supported by key moving averages, signaling improving demand and potential upside toward higher Fibonacci extension targets...
Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers
Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation...
The Big 3: ORCL, JNJ, SBUX
Dan Deming urges investors to stay nimble as markets grapple with crude oil, gold, and silver volatility. That said, he sees trading opportunities available in the markets.
JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company
Question: What caused JNJ stock to rise 70% since early 2025?
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi.
US FDA approves J&J's oral psoriasis pill
The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for psoriasis, the company said on Wednesday, paving the way for a more convenient treatment option for patients with...
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE offers an innovative new op...
Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
LIMA, Peru--(BUSINESS WIRE)--Johnson & Johnson announced the arrival in Peru of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation. This i...
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile Erda-iDRS has the potenti...
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients.
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patients...
US FDA approves JNJ's blood cancer drug
The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of blood cancer, making it the third drug cleared under the agency's new speedy review prog...
Johnson & Johnson launches website for direct-to-consumer sales
Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either don't have insurance or pay for their drugs out of pocket.
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocal...
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaqui...
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand...
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-th...
Does JNJ Stock Still Offer Value?
Up 17% through February 2026, Johnson & Johnson stock (NYSE: JNJ) is riding a wave of momentum fueled by a "triple threat" of high-growth oncology sales, a massive MedTech rebound, and a surprise earn...
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease cont...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Jo...